Our proven executive team brings deep, diverse cell therapy and oncology experience and is committed to developing safe, effective, and accessible NK cell therapies for cancer. Artiva's Board of Directors and Advisors bring years of expertise to help us realize the full potential of NK cell therapies.

Fred Aslan, M.D.

President and Chief Executive Officer

Tom Farrell

Founder and Chief Strategy Officer

Esther van den Boom, CPA

Chief Accounting Officer

Heather Raymon, Ph.D.

Vice President, Early Development and Program Management

Jennifer Bush

EVP, Chief Legal & People Officer

Peter Flynn, Ph.D.

Chief Operating Officer

Eugene Helsel

Vice President, Regulatory Affairs & Quality

Sungyong Won, Ph.D.

Vice President, Alliance Management

Michael Faerm

Chief Financial Officer

Jason Litten, M.D.

Chief Medical Officer

John Lim, Pharm.D.

Vice President, Clinical Operations

  • Twitter
  • LinkedIn

Privacy Policy  |  Terms
© Artiva Biotherapeutics, Inc., 2021